Board of Directors
Mr. Janzen has been involved in the Life Sciences industry for the past 19 years. He currently is the Founder and President of NorthView Ventures, an entity which invests in and provides strategic advisory services to a number of technology companies. Prior to that, he was President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over $300M from investors and completed over $1Billion in licensing deals during his tenure. In 2010 Cardiome’s lead product Brinavess was approved and launched in Europe by Merck. Prior to that, Mr. Janzen was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. Mr. Janzen is a past winner of Vancouver’s Top 40 under 40 award, is the past Chairman of Life Sciences British Columbia, has served as a Director of Biotech Canada and sits as a Director on a number of public and private boards.
Charles S. Carignan, MD
President and Chief Executive Officer
Dr. Carignan has more than twenty (20) years of experience in medical device development and holds vast experience as a Clinician, Med-Tech Executive and Chief Executive Officer. He also has strong regulatory and reimbursement experience. Dr. Carignan holds a Bachelor Degree from Yale University and obtained his Doctor of Medicine (M.D) from Columbia University in 1991. He trained in General Surgery at Columbia Presbyterian Medical Centre.
Most recently Dr. Carignan held the position of CEO at Rex Bionics Pty Limited. Prior to this, Dr. Carignan held the position of CEO at BionX Medical Technologies (now part of Ottobock) from July 2014 to March 2017. Previously Dr. Carignan was the Founder and CEO of NinePoint Medical, an OCT-based imaging technology initially used to image pathology in the esophagus, the Chief Medical Office of Novasys Medical Inc, the CMO of Boston Scientific, and the VP of Medical Affairs at Conceptus, acquired by Bayer.
Suzanne Foster, M.Ed, MPH
Mrs. Foster is a proven business leader, a breast cancer survivor, and a passionate patient advocate. As general manager of Medtronic Transformative Solutions, Mrs. Foster led the development and acquisition of several technologies that are improving the way critical procedures are performed and thereby advancing patient care. During her tenure at Medtronic, the business achieved double-digit revenue growth for the past seven years and experienced significant global market adoption.
Mrs. Foster is a frequent speaker on topics related to finding ways to advance technology and procedural innovation in breast cancer care. In March 2018, The National Consortium of Breast Centers (NCBC) awarded her with their Inspiration Award, which recognizes someone who has gone above and beyond towards improving breast cancer care. Mrs. Foster has also been recognized for her work in employee engagement and diversity. Notable achievements include:
— #1 Best Place to Work in New Hampshire, Business NH Magazine, 2014-2017
— Business Excellence Award in Manufacturing, New Hampshire Business Review, 2017
Mrs. Foster has a BA in Communication from University of New Hampshire, M.Ed in Psychology from Notre Dame College, JD Law from Suffolk Law School and a Masters in Public Health (Law and Health Policy) from Harvard School of Public Health.
Paul Magnin, PHD
Dr. Magnin spent 17 years as a key contributor to Hewlet-Packard's Ultrasound Imaging business. He was the General Manager of Hewlett-Packard's Imaging Systems business from January 1996 through 1998. From 1998 through 2003, Dr. Magnin was the President and CEO of LightLab Imaging, a medical device start-up company. LightLab developed a proprietary Optical Coherence Tomography technology that employs infrared light to make images with resolution on the micron scale for Cardiology, Endoscopy, Neurology, and Surgical Microscopy. Subsequently he was the Founder and President of Novelis, Inc. a privately funded start-up focused on guiding therapy for Interventional Cardiology applications. Novelis was sold to Volcano Corporation in 2008. Dr. Magnin is an advisor and board member of a number of medical device start-up companies. He holds over 16 patents and has authored over 20 scientific journal articles. He has been studying and working in medical imaging since 1977 while an undergraduate at Princeton University. In 1981 he completed his doctorate in Biomedical Engineering at Duke University where he was part of the Ultrasonic Imaging research team.
Frank Prendergast, MD
Dr. Prendergast has held senior positions within Mayo Clinic: Chair, Department of Biochemistry & Molecular Biology; Director for Research, Mayo Clinic Rochester,‘89-‘92. Member of the Board of Governors for Mayo Clinic in Rochester; Mayo Clinic Board of Trustees,‘92-‘09; Mayo Clinic’s Board of Governors, ‘99-‘06. Mayo Distinguished Investigator, Emeritus Director of the Mayo Clinic Comprehensive Cancer Center and Emeritus Director of Mayo Center for Individualized Medicine.
Frank also served extensively for the National Institutes of Health, Board of Advisors for Division of Research Grants; National Advisory General Medical Sciences Council; Board of Scientific Advisors of National Cancer Institute; National Cancer Advisory Board.
He has received the following honors and awards: Rhodes Scholarship; DSc Purdue University and University West Indies, Outstanding Graduate from University West Indies; Outstanding Graduate College of Biological Sciences from University of Minnesota; Musgrave Gold Medal Institute of Jamaica.
Frank holds a medical degree with honors from University of West Indies; Oxford University Rhodes Scholar M.A. degree in physiology. After internal medicine residency at Mayo Clinic, he obtained the Ph.D. degree in biochemistry at University of Minnesota/Mayo Graduate School.
Mr. Ireland is the Healthcare Principal at Roadmap Capital and brings more than 25 years of experience in healthcare. As the former Senior Vice-President, Business Development at TransTech Pharma, Mr. Ireland managed transactions in 2006 and 2010 with Pfizer and Forest Laboratories, respectively, valued in excess of $2 billion in potential upfront fees and milestones, each with recurring double-digit royalties. Mr. Ireland brings international experience in business development, clinical development, research, sales, marketing and executive management to Perimeter's board.
Mr. Cleland is co-founder and principal at Roadmap Capital, and Portfolio Manager of the Roadmap Innovation Funds. Mr. Cleland has a Bachelor of Arts (Honours, 1992/97) from Harvard University and earned his CFA designation in 2001. He was founding portfolio manager at Northern Rivers Capital Management (“Northern Rivers”), where he managed the Northern Rivers Innovation Fund from May of 2001 until Northern Rivers was acquired by BluMont Capital in February of 2010. He co-founded Roadmap Capital Inc. in the summer of 2013. Roadmap and its investors have now invested more than $120M in VC-stage tech companies. Sectors include semiconductors, material sciences, and medical devices. Mr. Cleland is now a member of the Board of Directors of Ubilite Inc and Perimeter Medical Imaging, and is an observer on the Board of Peraso Technologies and MMB Networks. Prior to Northern Rivers, Mr. Cleland also held various roles at Midland Walwyn Capital and Interward Capital Corporation.